VolitionRX Ltd has a consensus price target of $4.5 based on the ratings of 8 analysts. The high is $6 issued by EF Hutton on June 1, 2023. The low is $2 issued by Cantor Fitzgerald on August 16, 2023. The 3 most-recent analyst ratings were released by EF Hutton, Cantor Fitzgerald, and EF Hutton on June 7, 2024, May 16, 2024, and May 14, 2024, respectively. With an average price target of $3.67 between EF Hutton, Cantor Fitzgerald, and EF Hutton, there's an implied 459.80% upside for VolitionRX Ltd from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/07/2024 | Buy Now | 510.69% | EF Hutton | Tim Moore | $4 → $4 | Maintains | Buy | Get Alert |
05/16/2024 | Buy Now | 281.68% | Cantor Fitzgerald | Ross Osborn | → $2.5 | Reiterates | Overweight → Overweight | Get Alert |
05/14/2024 | Buy Now | 587.02% | EF Hutton | Tim Moore | $4.5 → $4.5 | Maintains | Buy | Get Alert |
03/27/2024 | Buy Now | 281.68% | Cantor Fitzgerald | Ross Osborn | → $2.5 | Reiterates | Overweight → Overweight | Get Alert |
03/27/2024 | Buy Now | 587.02% | EF Hutton | Tim Moore | $4.5 → $4.5 | Maintains | Buy | Get Alert |
01/02/2024 | Buy Now | 587.02% | EF Hutton | Tim Moore | $4.5 → $4.5 | Reiterates | Buy → Buy | Get Alert |
11/21/2023 | Buy Now | 587.02% | EF Hutton | Tim Moore | → $4.5 | Reiterates | Buy → Buy | Get Alert |
11/16/2023 | Buy Now | 281.68% | Cantor Fitzgerald | Ross Osborn | $2.1 → $2.5 | Maintains | Overweight | Get Alert |
10/30/2023 | Buy Now | 587.02% | EF Hutton | Tim Moore | → $4.5 | Initiates | → Buy | Get Alert |
08/16/2023 | Buy Now | 205.34% | Cantor Fitzgerald | Kyle Mikson | $3 → $2 | Maintains | Overweight | Get Alert |
06/01/2023 | Buy Now | 816.03% | EF Hutton | Tony Butler | → $6 | Assumes | → Buy | Get Alert |
03/16/2023 | Buy Now | 816.03% | EF Hutton | Constantine Davides | → $6 | Reiterates | → Buy | Get Alert |
02/01/2023 | Buy Now | — | Benchmark | Bruce Jackson | — | Downgrade | Buy → Hold | Get Alert |
12/19/2022 | Buy Now | 816.03% | EF Hutton | Constantine Davides | → $6 | Initiates | → Buy | Get Alert |
08/23/2022 | Buy Now | 663.36% | Maxim Group | Jason McCarthy | $8 → $5 | Maintains | Buy | Get Alert |
08/15/2022 | Buy Now | 816.03% | Aegis Capital | Nathan Weinstein | $9 → $6 | Maintains | Buy | Get Alert |
11/16/2021 | Buy Now | 1274.05% | Aegis Capital | Nathan Weinstein | — | Maintains | Buy | Get Alert |
The latest price target for VolitionRX (AMEX:VNRX) was reported by EF Hutton on June 7, 2024. The analyst firm set a price target for $4.00 expecting VNRX to rise to within 12 months (a possible 463.38% upside). 10 analyst firms have reported ratings in the last year.
The latest analyst rating for VolitionRX (AMEX:VNRX) was provided by EF Hutton, and VolitionRX maintained their buy rating.
There is no last upgrade for VolitionRX
The last downgrade for VolitionRX Ltd happened on February 1, 2023 when Benchmark changed their price target from N/A to N/A for VolitionRX Ltd.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VolitionRX, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VolitionRX was filed on June 7, 2024 so you should expect the next rating to be made available sometime around June 7, 2025.
While ratings are subjective and will change, the latest VolitionRX (VNRX) rating was a maintained with a price target of $4.00 to $4.00. The current price VolitionRX (VNRX) is trading at is $0.71, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.